UK-based biotechnology firm Daniolabs says that it has begun a Phase I proof-of-concept trial of two developmental products, DL06001 and DL06002, for sialorrhoea and hyperhidrosis in Parkinson's disease, respectively. Both compounds are novel combinations of established drugs that have been identified under the company's reprofiling policy.
Tony Sedgwick, Daniolabs chief executive, said: "we are delighted that the company's first clinical trial for the alleviation of sialorrhoea and hyperhidrosis has begun," adding that both products have the potential to improve the quality of life of Parkinson's disease sufferers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze